Collegium Pharmaceutical
COLL
21.93
+0.05
+0.23%
Collegium Pharmaceutical
US · COLL
#3535 by market cap
Listed 2015
21.93
+0.05
+0.23%
Live - 5344 symbols - heartbeat 163s ago
· 2026-10-08 08:33
Pre-market
22.01
+0.36%
After-hours
21.93
0.00%
- Market cap
- 679.81M
- P/E (TTM)i
- 17.27
- P/Bi
- 2.18
- EPSi
- 1.73
- Div yieldi
- 0.00%
- 52W posi
- 2%
Reader sentiment
Are you bullish or bearish on COLL?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.22, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +23.62% YoY
Margins
- Gross margin
- 59.35%
- Operating margin
- 22.86%
- Net margin
- 8.05%
Key ratios & quality
- Enterprise valuei
- 1.10B
- Altman Z-Scorei
- 1.22
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 280.41M | 296.70M | 310.02M | 276.87M | 463.93M | 566.77M | 631.45M | 780.57M |
| Gross profit | 114.74M | 103.04M | 179.84M | 150.62M | 209.49M | 326.17M | 377.34M | 463.26M |
| Selling & admin expenses | 126.76M | 116.45M | 113.83M | 118.96M | 172.19M | 159.21M | 210.36M | 284.80M |
| Research & development | 8.66M | 10.34M | 9.77M | 9.45M | 3.98M | -- | -- | -- |
| Operating profit | -20.69M | -23.75M | 56.23M | 22.21M | 33.32M | 166.96M | 166.98M | 178.45M |
| Pretax profit | -39.13M | -22.72M | 27.58M | -3.37M | -28.85M | 75.73M | 98.57M | 92.62M |
| Tax | 0 | 0 | 830.00K | -74.89M | -3.85M | 27.58M | 29.38M | 29.75M |
| Net profit | -39.13M | -22.72M | 26.75M | 71.52M | -25.00M | 48.16M | 69.19M | 62.87M |
| Basic EPS | -1 | -1 | 1 | 2 | -1 | 1 | 2 | 2 |
| Diluted EPS | -1.19 | -0.68 | 0.76 | 1.86 | -0.74 | 1.29 | 1.86 | 1.73 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 177.76M | 188.00M | 209.36M | 205.45M | 193.52M | 199.88M |
| Gross profit | 97.32M | 108.38M | 129.17M | 128.38M | 117.25M | 110.29M |
| Selling & admin expenses | 76.42M | 73.64M | 67.10M | 67.64M | 86.35M | 106.59M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 20.90M | 34.75M | 62.07M | 60.74M | 30.90M | 3.70M |
| Pretax profit | 3.12M | 17.03M | 43.44M | 29.04M | 18.74M | -13.53M |
| Tax | 705.00K | 5.04M | 11.93M | 12.07M | 4.24M | 1.52M |
| Net profit | 2.42M | 11.98M | 31.51M | 16.96M | 14.50M | -15.05M |
| Basic EPS | 0 | 0 | 1 | 1 | 0 | 0 |
| Diluted EPS | 0.07 | 0.34 | 0.84 | 0.46 | 0.40 | -0.46 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 237.51M | 255.72M | 277.89M | 315.54M | 419.99M | 537.60M | 482.26M | 691.41M |
| Cash & ST investments | 146.63M | 170.02M | 174.12M | 186.43M | 173.69M | 310.55M | 162.76M | 386.68M |
| Inventory | 7.82M | 9.64M | 15.61M | 17.39M | 46.50M | 32.33M | 35.56M | 40.91M |
| Total assets | 291.25M | 306.30M | 643.84M | 692.08M | 1.17B | 1.14B | 1.66B | 1.66B |
| Total current liabilities | 189.13M | 201.77M | 239.45M | 279.57M | 433.73M | 457.92M | 509.51M | 440.03M |
| Short-term debt | 1.64M | 4.49M | 48.23M | 49.17M | 163.61M | 184.32M | 65.85M | 30.41M |
| Long-term debt | 9.86M | 7.67M | 209.59M | 201.63M | 538.45M | 483.84M | 787.91M | 780.33M |
| Total liabilities | 199,660,000.00 | 218,870,000.00 | 457,810,000.00 | 489,149,000.00 | 979,289,000.00 | 947,877,000.00 | 1,434,749,000.00 | 1,355,159,000.00 |
| Total equity | 91.59M | 87.43M | 186.03M | 202.93M | 194.84M | 195.43M | 228.84M | 301.68M |
| Retained earnings | -337.18M | -359.90M | -333.15M | -256.34M | -281.34M | -233.19M | -164.00M | -101.13M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 527.55M | 549.21M | 613.87M | 691.41M | 745.67M | 608.01M |
| Cash & ST investments | 197.77M | 222.15M | 285.86M | 386.68M | 421.75M | 129.47M |
| Inventory | 37.22M | 38.15M | 38.05M | 40.91M | 42.74M | 113.27M |
| Total assets | 1.63B | 1.59B | 1.61B | 1.66B | 1.65B | 2.14B |
| Total current liabilities | 486.71M | 464.61M | 452.93M | 440.03M | 434.97M | 589.86M |
| Short-term debt | 65.89M | 65.92M | 65.96M | 30.41M | 34.07M | 56.56M |
| Long-term debt | 773.13M | 758.34M | 743.53M | 780.33M | 770.20M | 1.04B |
| Total liabilities | 1,396,954,000.00 | 1,360,425,000.00 | 1,332,520,000.00 | 1,355,159,000.00 | 1,339,533,000.00 | 1,823,881,000.00 |
| Total equity | 234.43M | 232.21M | 274.81M | 301.68M | 312.42M | 311.91M |
| Retained earnings | -161.58M | -149.60M | -118.09M | -101.13M | -86.63M | -101.68M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 169.39M | 27.78M | 93.94M | 103.56M | 124.23M | 274.75M | 204.98M | 329.32M |
| Depreciation & amortization | 110.91M | 15.48M | 61.55M | 68.92M | 138.94M | 149.26M | 169.16M | 226.07M |
| Free cash flow | 145.04M | 21.35M | -279.83M | 101.61M | 122.61M | 274.29M | 203.33M | 327.58M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -30.00K | 0 | 0 | -47.86M | -14.06M | -75.00M | -60.03M | -25.10M |
| Ending cash balance | 146.63M | 170.02M | 176.66M | 188.97M | 176.24M | 239.99M | 96.61M | 252.16M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 55.40M | 72.44M | 78.44M | 123.05M | 57.11M | 71.32M |
| Depreciation & amortization | 56.56M | 56.61M | 56.51M | 56.40M | 55.94M | 64.77M |
| Free cash flow | 54.60M | 72.37M | 78.25M | 122.36M | 56.84M | 70.83M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 0 | 0 | -- | -- |
| Ending cash balance | 117.09M | 138.25M | 171.00M | 252.16M | 289.56M | 150.38M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -39.99 | -25.39 | 19.57 | 36.77 | -12.57 | 24.68 | 32.62 | 23.70 |
| ROA %i | -18.34 | -7.61 | 5.63 | 10.71 | -2.68 | 4.16 | 4.93 | 3.79 |
| ROIC %i | -18.93 | -22.39 | 19.42 | 19.00 | 4.23 | 10.29 | 11.37 | 10.08 |
| 5-year avg ROE %i | -- | -- | -38.82 | -14.34 | -4.32 | 8.61 | 20.21 | 21.04 |
| EBIT margin %i | -6.78 | -7.35 | 18.21 | 6.37 | 7.41 | 28.07 | 27.32 | 22.41 |
| FCF / sales %i | 51.72 | 7.19 | -- | 36.70 | 26.43 | 48.40 | 32.20 | 41.97 |
| Current ratioi | 1.26 | 1.27 | 1.16 | 1.13 | 0.97 | 1.17 | 0.95 | 1.57 |
| Quick ratioi | 1.19 | 1.20 | 1.08 | 1.05 | 0.82 | 1.07 | 0.77 | 1.36 |
| Debt / assetsi | 3.95 | 7.05 | 41.41 | 37.39 | 60.40 | 58.98 | 51.65 | 49.18 |
| LT debt / equityi | 10.76 | 19.56 | 117.38 | 103.28 | 280.00 | 250.71 | 346.72 | 260.03 |
| Interest coveragei | -0.94 | -24.00 | 1.95 | 0.84 | 0.54 | 1.91 | 2.33 | 2.13 |
| Revenue CAGR (3Y) %i | -- | 457.64 | 121.63 | -0.42 | 16.07 | 22.28 | 31.63 | 18.94 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | 21.65 | -1.10 | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -11.18 | 79.09 | -- | 26.01 | 38.76 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 19.23 | 16.16 | 22.96 | 23.70 | 27.41 | 17.61 |
| ROA %i | 3.20 | 2.74 | 3.60 | 3.79 | 4.57 | 2.57 |
| ROIC %i | 9.14 | 9.36 | 10.33 | 10.08 | 10.89 | 7.07 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 21.45 | 19.14 | 22.00 | 22.41 | 23.31 | 19.07 |
| FCF / sales %i | 29.59 | 28.54 | 38.21 | 41.97 | 41.42 | 40.62 |
| Current ratioi | 1.08 | 1.18 | 1.36 | 1.57 | 1.71 | 1.03 |
| Quick ratioi | 0.88 | 0.94 | 1.15 | 1.36 | 1.50 | 0.70 |
| Debt / assetsi | 51.75 | 52.06 | 50.64 | 49.18 | 48.92 | 51.34 |
| LT debt / equityi | 332.00 | 328.67 | 272.20 | 260.03 | 247.74 | 333.42 |
| Interest coveragei | 1.84 | 1.64 | 1.94 | 2.13 | 2.40 | 2.02 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- BELBUCA is the largest reported line at 28.85% of revenue, across 9 reported segments.
- No single line clears half of revenue; Jornay PM is next at 23.04%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
BELBUCA28.85%
Jornay PM23.04%
Xtampza Extended-release (ER)22.52%
Nucynta Extended-release (ER)7.87%
Nucynta Immediate-release (IR)7.18%
Azstarys6.46%
Symproic1.51%
Nucynta Extended-release (ER) Authorized Generic (AG)1.39%
Nucynta Immediate-release (IR) Authorized Generic (AG)1.18%
Quote time 2026-10-08 08:33:16 · For reference only, not investment advice and not tailored to your situation.